The significance of CR as an endpoint in frail patients with multiple myeloma

Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the significance of complete response (CR) as an endpoint for frail patients with multiple myeloma. She notes that while high measurable residual disease (MRD) negativity and complete response (CR) rates are seen in some studies, progression-free survival (PFS) curves may not fully reflect the depth of response due to high discontinuation rates. She emphasizes the importance of balancing efficacy and toxicity, as each patient has a threshold for drug density that can be administered. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.